Advertisement
UK markets closed

  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     

  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     

  • CRUDE OIL

    78.88
    +0.40 (+0.51%)
     

  • GOLD FUTURES

    2,320.30
    -10.90 (-0.47%)
     

  • DOW

    38,916.68
    +64.41 (+0.17%)
     

  • Bitcoin GBP

    50,708.36
    +29.46 (+0.06%)
     

  • CMC Crypto 200

    1,317.48
    -47.64 (-3.49%)
     

  • NASDAQ Composite

    16,380.91
    +31.66 (+0.19%)
     

  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     
Money:

The retirement income gap no-one is talking about

People are living longer than ever before and this can impact how you plan for retirement

Galapagos, GSK successfully conclude phase 2a study of skin disease drug

Reuters - UK Focus

BRUSSELS, April 17 (Reuters) - Belgian biotech group Galapagos NV (Other OTC: GLPGF - news) on Thursday said it has successfully concluded the phase 2a study of a skin disease drug it is developing with Britain's GlaxoSmithKline PLC (Other OTC: GLAXF - news) .

Galapagos tested drug GSK2586184 on 66 patients with chronic psoriasis and observed a 75 percent improvement in significantly more patients than in the placebo group.

GSK, which owns the drug's commercial rights, will decide whether to proceed with clinical trials, Galapagos said in a statement.

Galapagos said it could receive a milestone payment of up to 34 million euros ($46.94 million) as well as double-digit royalties as the programme proceeds towards commercialisation.

($1 = 0.7243 Euros) (Reporting by Robert-Jan Bartunek; Editing by Christopher Cushing)